ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 156 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2015. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2018 | $4,751,000 | +16.1% | 65,683 | +5.6% | 0.79% | +7.9% |
Q4 2017 | $4,093,000 | -12.1% | 62,172 | -33.1% | 0.73% | +18.4% |
Q3 2017 | $4,656,000 | +0.4% | 92,899 | -7.3% | 0.62% | -19.2% |
Q2 2017 | $4,636,000 | +2.3% | 100,170 | -21.9% | 0.77% | +7.3% |
Q1 2017 | $4,530,000 | -45.2% | 128,300 | +43.6% | 0.71% | -25.2% |
Q1 2015 | $8,272,000 | +11.2% | 89,335 | -51.5% | 0.96% | -8.0% |
Q4 2014 | $7,442,000 | +341.4% | 184,020 | +167.0% | 1.04% | +202.6% |
Q3 2014 | $1,686,000 | – | 68,921 | – | 0.34% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 4,468,835 | $22,344,000 | 10.09% |
Altium Capital Management LP | 2,515,785 | $12,579,000 | 3.47% |
Deep Track Capital, LP | 5,641,668 | $28,208,000 | 1.99% |
Paradigm Biocapital Advisors LP | 839,257 | $4,196,000 | 1.20% |
SABBY MANAGEMENT, LLC | 940,400 | $4,702,000 | 0.68% |
Monaco Asset Management SAM | 500,000 | $2,500,000 | 0.62% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,000,000 | $25,000,000 | 0.52% |
CVI Holdings, LLC | 1,460,595 | $7,303,000 | 0.48% |
PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $13,566,000 | 0.38% |
Rhenman & Partners Asset Management AB | 1,000,000 | $4,960,000 | 0.33% |